Rituximab for plasma exchange-dependent recurrent focal segmental glomerulosclerosis after renal transplantation

NDT Plus

Volumn 1, Issue 2, 2008, Pages 85-88

  Deegens, Jeroen K J ^a   Wetzels, Jack F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Focal segmental glomerulosclerosis; Recurrence; Renal transplantation; Rituximab

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL TOXICITY; GRAFT FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MONOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; RELAPSE; REMISSION; SCHOOL CHILD; TREATMENT FAILURE;

EID: 41749120816     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfm048     Document Type: Article

References (24)

1. Deegens JK, Andresdottir MB, Croockewit S et al. Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int 2004; 17: 151-157
2. Savin VJ, Sharma R, Sharma M et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334: 878-883
3. Matalon A, Markowitz GS, Joseph RE et al. Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clin Nephrol 2001; 56: 271-278
4. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006; 354: 1961-1963
5. Ahmed MS, Wong CF. Rituximab and nephrotic syndrome: A new therapeutic hope? Nephrol Dial Transplant 2007
6. Nozu K, Iijima K, Fujisawa M et al. Rituximab treatment for post-transplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005; 20: 1660-1663
7. Marks SD, McGraw M. Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatr Nephrol 2007; 22: 158-160
8. Hristea D, Hadaya K, Marangon N et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007; 20: 102-105
9. Kamar N, Faguer S, Esposito L et al. Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 2007; 67: 250-254
10. Cossmann J, Scheuermann EH, Porubsky S et al. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomeruloscierosis. Transpl Int 2007; 20: 558-562
11. Meyer TN, Thaiss F, Stahl RA. Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 2007; 20: 1066-1071
12. Yabu JM, Ho B, Scandling JD et al. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 2007
13. El-Firjani A, Hoar S, Karpinski J et al. Post-transplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy. Nephrol Dial Transplant 2007
14. Shalhoub RJ. Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 1974; 2: 556-560
15. Koyama A, Fujisaki M, Kobayashi M et al. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991; 40: 453-460
16. Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999; 169: 107-121
17. Sanz I, Anolik J. Reconstitution of the adult B cell repertoire after treatment with rituximab. Arthritis Res Ther 2005; 7: 175-176
18. Smith KG, Jones RB, Burns SM et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-2982
19. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum 2005; 52: 501-513
20. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006; 66: 1933-1948
21. Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-826
22. Leandro MJ, Cooper N, Cambridge G et al. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) 2007; 46: 29-36
23. Hoyer BF, Moser K, Hauser AE et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004; 199: 1577-1584
24. Manz RA, Radbruch A. Plasma cells for a lifetime? Eur J Immunol 2002; 32: 923-927